Basilea berichtet über Präsentationen zu Isavuconazol (Cresemba®) und Ceftobiprol (Zevtera®) auf dem Europäischen Kongress für Klinische Mikrobiologie und Infektionskrankheiten (ECCMID)

    NEXT STORY
    DEINOVE invited to present at the 29th congress of the European Society of Clinical Microbiology and Infectious Diseases
    PREV STORY
    Recro Pharma Announces Presentation of New Meta-Analysis for IV Meloxicam at the 44th Annual Regional Anesthesiology and Acute Pain Medicine Meeting
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Fortress Biotech Appoints Michael G. King, Jr. as Entrepreneur in Residence

    NEW YORK, May 15, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) (“Fortress”), a ...

    author_avatar
    NASDAQ Market News

    Merit Medical Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters’ Over-Allotment Option

    SOUTH JORDAN, Utah, July 30, 2018 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) ...

    author_avatar
    NASDAQ Market News

    Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China

    author_avatar
    NASDAQ Market News